Published by Southwest Clinical Research | Dallas, TX Reading time: ~6 minutes
If you've been diagnosed with narcolepsy or you're in the process of figuring out whether you have it, you've likely encountered the terms "Type 1" and "Type 2." They sound simple enough. But in practice, the distinction between them is one of the most important and least-explained aspects of narcolepsy care.
Both types share the same hallmark symptom: excessive daytime sleepiness that doesn't resolve with more rest, that interrupts work and relationships, that makes ordinary life feel like a constant uphill climb. In that way, the lived experience of NT1 and NT2 can look very similar from the outside.
But underneath the surface, the biology is different. The diagnostic criteria are different. The treatment approaches are different. And now, the research options are different too.
Understanding which type you have and why it matters is one of the most useful things you can do for your own care.
Narcolepsy Type 1: the role of orexin and cataplexy
Narcolepsy Type 1 is defined by two things occurring together: excessive daytime sleepiness and cataplexy, the sudden, emotion-triggered loss of muscle tone described in Post 2 of this series.
The biology of NT1 is now fairly well understood. In the vast majority of people with NT1, the neurons in the hypothalamus that produce orexin, also called hypocretin have been destroyed. Orexin is the neurochemical responsible for maintaining stable wakefulness and regulating the boundary between sleep and waking. Without it, the brain loses its ability to stay reliably awake during the day, to prevent REM sleep from intruding at inappropriate times, and to maintain muscle tone in response to emotional triggers.
The destruction of orexin neurons is believed to be autoimmune in nature the body's own immune system, for reasons not yet fully understood, turns against these specific brain cells. The result is a dramatic, often near-total loss of orexin that is permanent and progressive in its early stages before stabilizing.
This is why NT1 can be confirmed through a cerebrospinal fluid test: orexin levels in people with NT1 are typically extremely low at or below 110 pg/mL, compared to normal levels above 200 pg/mL. This biological marker makes NT1 one of the more definitively diagnosable neurological conditions, when the right tests are done.
Cataplexy can range from subtle a brief jaw drop, slight knee buckle, or momentary slurring of speech during a laugh to complete, where the person collapses fully while remaining conscious. It's triggered almost exclusively by positive emotions in many people: laughter, excitement, pride, surprise. Some people experience it dozens of times a day. Others only a handful of times a year. Either way, its presence is the clearest clinical signal of NT1.
Narcolepsy Type 2: same sleepiness, different story
Narcolepsy Type 2 involves the same crushing daytime sleepiness as NT1, the sudden sleep attacks, the cognitive fog, the inability to feel rested no matter how much sleep you get. What's absent in NT2 is cataplexy.
The underlying biology of NT2 is less clearly mapped than NT1. Orexin levels in people with NT2 are typically normal or only mildly reduced which means the orexin deficiency that defines NT1 isn't the explanation here. What's disrupting the sleep-wake cycle in NT2 is still an active area of research, and one of the reasons NT2 clinical trials are so scientifically valuable right now.
NT2 is diagnosed primarily through clinical evaluation and sleep testing the overnight polysomnography and Multiple Sleep Latency Test described in Post 3. On the MSLT, people with NT2 fall asleep very quickly across naps and, importantly, enter REM sleep in two or more of those naps. This pattern reflects the same underlying dysregulation of REM sleep seen in NT1, even if the cause is different.
One nuance worth knowing: some people initially diagnosed with NT2 are later reclassified as NT1 when cataplexy symptoms emerge or become more recognizable over time. Cataplexy can be subtle, especially early in the course of the disease, and not everyone reports it clearly on a first evaluation. This is another reason thorough, specialist-led assessment matters.
How treatment approaches differ
Current treatments for narcolepsy focus on managing symptoms there is no cure yet for either type, which is a key reason research is so urgently needed.
For NT1, treatment typically addresses both the excessive daytime sleepiness and the cataplexy. Medications that promote wakefulness such as modafinil, armodafinil, or sodium oxybate are commonly used. Sodium oxybate (and its newer low-sodium formulation) is particularly effective for cataplexy and nighttime sleep consolidation, and is one of the few treatments approved specifically for NT1. Antidepressants at lower doses are sometimes used off-label to reduce cataplexy frequency.
For NT2, the treatment approach centers on managing sleepiness, since cataplexy is not a factor. Wake-promoting agents are typically the first line. Because the underlying biology is less well understood, treatment for NT2 can feel more like trial and error, and not every patient finds a regimen that fully addresses their symptoms.
This gap between what current treatments can offer and what people with narcolepsy actually need is precisely what clinical research is working to close.
Why research treats them as separate conditions
You might wonder: if both types share excessive daytime sleepiness, why not just study them together?
The answer comes down to biology and precision.
Because NT1 and NT2 have different underlying mechanisms, a treatment that works through the orexin pathway may be highly effective for NT1 but irrelevant for NT2. Enrolling both types in the same study without accounting for this would produce muddied data making it harder, not easier, to understand what's actually working and for whom.
Separating the studies allows researchers to design interventions tailored to the specific biology of each type. It means that if a treatment works, the evidence is clean and actionable. It means that NT2 which has historically received less research attention than NT1 gets a dedicated scientific focus rather than being treated as a footnote.
It also means that participants benefit from being studied alongside people who have the same type as they do, with assessments and endpoints designed for their specific experience.
Which study is right for you?
At Southwest Clinical Research in Dallas, we currently have a narcolepsy study enrolling, one designed specifically for both types.
The Onstride Study is for adults diagnosed with Narcolepsy Type 1 and 2 narcolepsy with/without cataplexy. If you experience sudden muscle weakness triggered by emotion alongside excessive daytime sleepiness, and you've received an NT1or NT2 diagnosis (or are in the process of being evaluated), we encourage you to reach out.
Not sure which type you have? That's more common than you might think, and our team can help you think it through. Reach out and tell us what you're experiencing we'll take it from there.
Our study offers commitment to participant care:
There is no cost to inquire, no obligation to enroll, and no pressure at any stage. The first conversation is simply that a conversation.
Find out which study is right for you:
🌐 southwestclinicalresearch.com/narcolepsy-clinical-trial 📞 Call: (469) 893-1242 💬 Text: (214) 393-6863 📧 Email: research@swmedicalgroup.com
Location: 8989 Harry Hines Blvd, Suite 200 | Dallas, TX 75235
Southwest Clinical Research is committed to advancing healthcare through ethical, participant-centered clinical research. We prioritize diversity in enrollment and are proud to serve the Dallas-Fort Worth community.
Up next the final post in this series: Living well with narcolepsy: strategies from people who get it.
